Studying the synergistic effect of mycotoxins exposure and Epstein Barr virus infection in causing Burkitt’s Lymphoma in AfricaDr Grace Akinyi Odongo, International Agency for Research on Cancer (IARC), part of the World Health Organisation (WHO)
Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL)Dr Marc Mansour, UCL Cancer Institute
A pilot Investigation of the ZFP36L1 protein as a candidate therapeutic target in osteosarcoma cellsDr John Murphy, University of Westminster
Optimising the use of repurposed drugs to improve the treatment of children with ALLProf. Julie Irving, Newcastle University
“BENCHISTA” - Benchmarking International Survival by Toronto stAgeProf. Kathy Pritchard-Jones and Dr Gemma Gatta, University College London, UCL Great Ormond Street Institute of Child Health; and Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan
Investigating late effects of surviving childhood cancerDr Defne Saatci, University of Oxford
One of the greatest medical success stories of the last century is the amazing growth in the survival from childhood cancer. Fifty years ago, only a quarter of children diagnosed with cancer survived. Today, more than 80 per cent of young patients can be successfully treated.
However, cancer still claims the lives of around 250 children every year in the UK. And unfortunately the children who survive may be left with serious health and developmental problems as a result of the intensive treatments used to save their young lives.
Through our investment in research, we are taking forward our understanding of childhood cancer, to give new insights into ways of treating young patients with even the most difficult forms of cancer. We hope to drive up the survival rate still further whilst reducing the risk of harm.